Australia markets closed

ALK-Abelló A/S (0OIR.IL)

IOB - IOB Delayed price. Currency in DKK
Add to watchlist
149.450.00 (0.00%)
At close: 05:35PM BST
Full screen
Previous close149.45
Open155.00
Bid0.00 x 0
Ask0.00 x 0
Day's range154.00 - 158.40
52-week range70.70 - 159.20
Volume3,248
Avg. volume19,774
Market cap30.001B
Beta (5Y monthly)0.31
PE ratio (TTM)92.83
EPS (TTM)1.61
Earnings date23 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend date16 Mar 2017
1y target estN/A
  • GlobeNewswire

    ALK upgrades its full-year revenue and earnings outlook

    ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect better than expected sales performance in Q2 and an improved outlook for the remainder of the year. Revenue is now expected to grow by 12-15% in local currencies (prev.: 10-13%).The EBIT margin is now expected to improve to 18-20% (prev.: 17-19%) vs. 14% in 2023. The full-year revenue outlook has been upgraded primarily to reflect a continued strong momentum in tablet sales, impro

  • GlobeNewswire

    ALK provides update on regulatory process for the house dust mite allergy tablet in China

    ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that it has decided to withdraw the Biologic License Application (‘BLA’) for its house dust mite (‘HDM’) sublingual allergy immunotherapy tablet in China. ALK will continue to work with the authorities to obtain regulatory approval of the HDM tablet in China, which may involve establishing additional clinical data in Chinese patients. The delay in the regulatory approval process does not impact ALK’s financial guidance for 2024, or its ability t

  • GlobeNewswire

    ALK launches new growth strategy and 2028 financial ambitions

    ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the Board of Directors has adopted a new corporate strategy (Allergy+) and 2028 financial ambitions. Allergy+ aims to further strengthen ALK’s leadership in allergy immunotherapy, establishing a leading position in food allergy and anaphylaxis, as well as pursuing new innovations to address adjacent allergic conditions with high unmet needs. The strategy targets average revenue growth of minimum 10% in local currencies (5-year CAGR) until 2